Welcome to our dedicated page for LIXTE BIOTECHNOLOGY HOLDINGS SEC filings (Ticker: LIXTW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on LIXTE BIOTECHNOLOGY HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into LIXTE BIOTECHNOLOGY HOLDINGS's regulatory disclosures and financial reporting.
Director Jason David Sawyer reported a compensation-related change in his equity awards in LIXTE BIOTECHNOLOGY HOLDINGS, INC. On April 15, 2026, he agreed with the company to cancel 25,000 options to purchase common stock with a $3.59 exercise price, which otherwise would have vested over time. In exchange, he received 25,000 restricted share units (RSUs), each representing a contingent right to one share of common stock. The RSUs were granted under the company’s 2020 Stock Incentive Plan and vested immediately upon grant, resulting in 25,000 shares of common stock held directly after the transactions. This sequence is a restructuring of equity compensation rather than an open-market buy or sell.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. director Guy Warren Primus exchanged equity awards on April 15, 2026. The company canceled 25,000 stock options with a $4.05 exercise price and, under a Stock Option Cancellation Agreement, granted 25,000 restricted share units that vest immediately, giving him 25,000 shares of common stock directly owned after the transaction.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. director Michael Andrew Holloway restructured his equity compensation on April 15, 2026. He disposed of options to purchase 25,000 shares of common stock back to the company and, in exchange, received 25,000 restricted share units (RSUs).
Each RSU represents a right to receive one share of common stock, and all 25,000 RSUs vested immediately upon grant, subject to continued service conditions in the plan documents. Following these transactions, Holloway directly holds 25,000 shares of common stock, reflecting this grant-and-cancel structure rather than an open-market trade.
Lixte Biotechnology Holdings reports itself as a clinical-stage cancer company with no product revenue, expanding from its LB-100 drug platform into proton therapy through majority ownership of Liora Technologies Europe.
The company recorded a net loss of $6,009,520 for 2025 versus $3,585,965 in 2024 and an accumulated deficit of $58,077,213, and its auditors raised substantial doubt about its ability to continue as a going concern. Management expects existing cash to fund operations only into late 2026 and plans to raise additional capital by mid‑2026.
LB-100 is being evaluated in multiple oncology trials, including combinations with doxorubicin, PD‑1 and PD‑L1 checkpoint inhibitors in ovarian clear cell carcinoma, metastatic microsatellite-stable colorectal cancer and soft tissue sarcoma, supported by collaborations with MD Anderson, GSK and the Netherlands Cancer Institute. Lixte has decided not to fund the randomized Phase 2 sarcoma trial, avoiding about $3,095,000 in planned costs, and settled a consulting dispute for $100,000. The company highlights an extensive global patent estate around LB‑100, its combinations and prodrugs, and outlines Liora’s LiGHT proton therapy prototype, which targets lower-cost, high-throughput proton treatment and FLASH-capable radiotherapy but will require further investment and regulatory clearance before clinical use.
Lixte Biotechnology Holdings, Inc. updated its executive compensation by amending the employment agreement of Chief Executive Officer Geordan Pursglove. Effective January 1, 2026, his annual base salary increased from $240,000 to $360,000, as approved by the Compensation Committee and Board of Directors. The salary Amendment, dated March 18, 2026, is filed as Exhibit 10.1 and incorporated by reference into this report.
Lixte Biotechnology Holdings entered into an Amended and Restated Share Exchange Agreement with its subsidiary Liora Technologies Europe and Orbit Capital, dated March 6, 2026 and effective as of November 21, 2025. This agreement consolidates prior arrangements into a single structure.
Under earlier agreements, Lixte had acquired 100% of Liora, issued 2,700 shares of Series C Preferred Stock to Orbit and entered a royalty agreement, which was later terminated. Orbit then exchanged those preferred shares for 700,000 shares of Lixte common stock and reacquired a 20% ownership interest in Liora. The new agreement is intended to reflect these combined transactions and the parties’ agreed ownership structure.
LIXTE Biotechnology Holdings, Inc. entered into an Allocation Deed and a Consultancy Agreement with its subsidiary Liora Technologies Europe Ltd. and consultant Sidney Braun. Braun becomes CEO and a director of Liora, with a GBP 50,000 signing bonus and a GBP 25,000 monthly retainer, both exclusive of VAT.
Under the Allocation Deed, Braun is entitled to 20% of the net purchase price if there is a sale of Liora or any Liora successor. LIXTE also issued a press release highlighting Braun’s healthcare background and Liora’s LiGHT System proton therapy technology for cancer treatment.
Lixte Biotechnology Holdings, Inc. filed a current report describing a recent treasury move into digital assets. On September 10, 2025, the company issued a press release announcing an initial purchase of digital currency totaling $2.6 million.
The disclosure is furnished under Regulation FD, meaning it is provided for informational purposes and is not treated as filed financial information under securities laws. The report also includes standard forward-looking statement cautions about risks and uncertainties that could cause actual results to differ from expectations.
Lixte Biotechnology Holdings, Inc. director Guy Primus filed an initial insider ownership report on Form 3 as of 09/01/2025. The filing states that no securities of the company are beneficially owned, and both the non-derivative and derivative securities tables are blank.
Peter Stazzone, appointed Chief Financial Officer of Lixte Biotechnology Holdings, Inc., was granted options to buy 50,000 shares of common stock at an exercise price of $4.45 per share. The options vest in four equal tranches: 25% on 09/01/2025, 25% on 12/15/2025, 25% on 03/15/2026, and 25% on 06/15/2026, subject to continuous service and possible acceleration on certain events. Each option covers one share and the options expire five years after the grant date, making the exercisable common shares underlying the grant 50,000.